Liver Diseases  >>  ALS-2200  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ALS-2200 / J&J, Vertex, BMS
NCT01790100: A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

Checkmark EASL 2014
Mar 2014 - Mar 2014: EASL 2014
Completed
2a
20
RoW
VX-135, Ribavirin
Alios Biopharma Inc., Vertex Pharmaceuticals Incorporated
Chronic Hepatitis C
06/14
06/14
NCT01726946: A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

Completed
2
10
US
VX-135, ribavirin
Vertex Pharmaceuticals Incorporated
Chronic Hepatitis C
02/14
02/14
NCT01842451: A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C

Checkmark EASL 2014
Mar 2014 - Mar 2014: EASL 2014
Checkmark From 100mg and 200mg arms of 12-week combination therapy trial (VX-135+daclatasvir) in G1 hep C infected patients
Jan 2014 - Jan 2014: From 100mg and 200mg arms of 12-week combination therapy trial (VX-135+daclatasvir) in G1 hep C infected patients
Completed
2
23
RoW
VX-135, Daclatasvir
Vertex Pharmaceuticals Incorporated
Chronic Hepatitis C, CHC, HCV, Hepatitis C
05/14
05/14

Download Options